Cagrilintide
The second satiety signal, coming from the pancreas rather than the gut.
| Property | Value |
|---|---|
| Type | Amylin analogue with a fatty acid tail |
| Receptor | Amylin receptors |
| Research field | Satiety, appetite, stomach emptying |
| Research status | Clinical research ongoing |
| Form | Powder in a vial, also in blends |
What it is
A copy of amylin, the hormone the pancreas releases alongside insulin. Natural human amylin clumps into fibres and is therefore unworkable; cagrilintide is modified so that does not happen, with a fatty acid tail added for duration.
How it works
Amylin slows stomach emptying, curbs glucagon and sends a satiety signal to the brainstem. That route is separate from GLP-1, which is why the two are often combined in research.
What the research shows
The combination with semaglutide is known in the literature as CagriSema and is one of the most closely watched lines of research in this field. The thinking is that two independent routes together give a stronger signal than driving one route hard.
Research status
In clinical research in humans.
Practical
Often supplied as a blend with a GLP-1 analogue. With such a mixture, ask for a certificate in which both substances were measured separately.
This site is made by the team behind Apex Bio Research, a Dutch supplier of research peptides with a certificate of analysis per batch.
Visit the shopThis site explains what the scientific literature says about peptides. It is not medical advice and not a set of instructions. The substances discussed here are research compounds: they are not approved for use in humans or animals. If you have a health question, see a doctor.
Read next
Amylin: the second satiety signal
Besides GLP-1 there is a second route to satiety, through the pancreas. What amylin does and why it is often studied next to a GLP-1 analogue.
Judging blends: why a mixture follows different rules
With two or more peptides in a vial a purity figure is meaningless. What to ask for instead and where it goes wrong.
Retatrutide
Retatrutide in brief: the triple agonist on GLP-1, GIP and glucagon, and what the research shows.